Time New York: Mon 23 Jul 13:39 pm  |  Save 15% on H&R Block Online


GTx’s (GTXI) Enobosarm Positive in Phase II, Shares Down


GTx, Inc. GTXI announced positive top-line data from a phase II study, evaluating lead pipeline candidate, enobosarm 3 mg (GTx-024), for treating postmenopausal women with stress urinary incontinence (SUI). Data from the study was presented at International Continence Society (ICS) Annual Meeting.

Shares of GTx have decreased almost 9% despite the good news as the data announced was probably below market expectations. However, shares of the company have outperformed the industry so far this year. The stock has surged 42.4% compared with the broader industry's increase of 16%.

The open-label, non-placebo controlled, proof-of-concept phase II study was conducted on 17 postmenopausal women with SUI. The trial met primary endpoints and revealed that women treated with enobosarm experienced significant reduction (50% or greater) in incontinence episodes per day compared with baseline, which sustained for up to seven months following completion of treatment. Mean stress leaks declined by 83% from baseline over a period of 12 weeks. Adverse events reported in the study were minimal.

Based on results from the study, GTx started a randomized, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of enobosarm across two doses (1 mg and 3 mg) compared with placebo in postmenopausal women with SUI.

Investors are reminded that presently, the company is conducting another phase II study, evaluating enobosarm in patients whose advanced breast cancer is both estrogen receptor (ER) positive and androgen receptor (AR) positive. Top-line data from the program is expected later in 2017.

Notably, enobosarm has already been assessed in 24 completed or ongoing clinical trials for SUI enrolling over 1,700 subjects, of which, approximately 1,200 were treated with enobosarm at doses, ranging from 0.1-100 mg.

Stocks to Consider

Some stocks worth considering in the pharma sector are Akebia Therapeutics, Inc. AKBA, Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD, all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Akebia’s loss per share estimates narrowed from $4.14 to $3.85 for 2017 and from $1.98 to $1.88 for 2018 over the last 60 days. Its share price soared 69% so far this year.

Aduro Biotech’s loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.55 to $1.24 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.

ACADIA’s loss per share estimates lessened from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.

See these buy recommendations now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.